Drug intelligence / Profile preview

ADGN-902

Development stage: Preclinical
Lead developer: DIVINCELL
Modality: Peptides, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

ADGN-902 is a preclinical-stage peptide-mRNA nanoparticle therapeutic designed to restore BRCA1 tumor suppressor function in BRCA1-mutated cancers, particularly breast cancer. Developed by Aanastra (formerly Aadigen) in collaboration with Divincell, the drug consists of a proprietary BRCA1-derived mRNA sequence complexed with a proprietary short amphipathic peptide nanocarrier. This formulation enables selective delivery and expression of BRCA1 in tumor cells. ADGN-902 specifically targets and reduces the proliferation of cancer cells expressing N-terminal truncated BRCA1.

Targets

BRCA1 (Breast cancer type 1 susceptibility protein)

Beyond the preview

Go deeper on ADGN-902.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADGN-902.

Explore the full profile